Categories: DNAHealthcareNews

Alira Health Secures Up to $100M Growth Debt Facility from Symbiotic Capital to Propel Strategic Expansion and Patient-Enabled Innovation

FRAMINGHAM, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) — Alira Health, a global healthcare consulting and technology firm transforming the patient journey, announced today the securing of up to $100 million in growth debt from Symbiotic Capital, a premier healthcare and life sciences investor. This funding will drive Alira Health’s strategic growth, enhance its innovative technology platforms, and support solutions that empower patients and create value for life sciences companies.

“This significant investment from Symbiotic Capital validates our vision for patient-centered healthcare,” said Gabriele Brambilla, Co-CEO of Alira Health. “The funding will enable us to accelerate patient-enabled innovation, scale our integrated solutions, and strengthen the technology platforms that serve both patients and life sciences companies.”

To facilitate this expansion, Alira Health has established a Chief Operating Officer (COO) role, appointing Andrea Pulvirenti, a seasoned company leader, to oversee operations and manage the scaling of its global presence.

“We’re excited to partner with Alira Health as they redefine the biopharma and medtech research landscape,” said Himani Bhalla, Chief Investment Officer and Co-Founder of Symbiotic Capital. “Their patient-first approach and integrated solutions are advancing the life sciences ecosystem and improving patient outcomes.”

For more information about Alira Health, visit www.alirahealth.com.

About Alira Health

Alira Health is a global healthcare consulting and technology firm dedicated to advancing the life sciences ecosystem. By integrating evidence-based insights with cutting-edge technology, Alira Health empowers clients in pharma, medtech, and biotech to improve patient outcomes. Learn more at www.alirahealth.com.

About Symbiotic Capital

Symbiotic Capital is a healthcare credit firm that brings together decades of experience across life sciences, finance, and entrepreneurship. Symbiotic Capital’s integration into a global ecosystem empowers it to provide lending solutions to fuel the growth of established healthcare companies around the world.

For more information, please visit www.symbcap.com.

CONTACT: John McLaughlin
617-872-4572
john.mclaughlin@alirahealth.com

Staff

Recent Posts

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

21 hours ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

21 hours ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

21 hours ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

21 hours ago

Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger

CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or…

21 hours ago

Park Dental Partners Announces Dates for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK), a leading…

21 hours ago